Our Take
The pathway is real and mechanism is solid, but the therapeutic leap from mouse models to human drugs remains speculative and years away.
Why it matters
This work explains how cells defend themselves after pathogens breach the initial immune barrier, and identifies TRIM21 as a potential drug target. For immunology and infectious disease, a validated intracellular defense route changes how we think about backup immunity.
Do this week
Immunology teams: review the Molecular Cell paper for TRIM21 binding kinetics and consider whether your current antibody-based therapies could exploit ADX tagging in preclinical models.
MRC researchers map antibody-directed xenophagy
Scientists at the MRC Laboratory of Molecular Biology, led by Leo James and Tyler Rhinesmith, identified a previously undescribed cellular mechanism for fighting infection from inside already-infected cells. They named it antibody-directed xenophagy (ADX).
The pathway works this way: antibodies coat invading bacteria or viruses in the bloodstream. Some antibody-tagged pathogens still cross the cell membrane. Once inside, the intracellular protein TRIM21 recognizes the antibodies, tags the pathogen with ubiquitin, and signals the cell's autophagy machinery to seal the invader inside an autophagosome and digest it in the lysosome.
Using genome-wide CRISPR-Cas9 knockout screens, quantitative confocal microscopy, and super-resolution imaging, the team observed this process in real time. They tested it on adenoviruses in multiple human cell lines and on Salmonella bacteria in living mouse models. The ADX pathway worked in both cases, suggesting the mechanism is broadly applicable across cell types and diverse pathogen architectures.
James's lab had previously shown that TRIM21 binds antibody-coated viruses and triggers degradation. This study reveals the missing link: the stepwise recruitment of autophagy components around the ubiquitinated pathogen, culminating in lysosomal digestion. The team observed LC3 (an autophagosome marker) assembling around individual viral particles and tracked the delivery of virus-containing compartments into acidic lysosomes.
The findings appear in a peer-reviewed paper in Molecular Cell, titled "TRIM21 induces selective autophagy of viruses and bacteria." TRIM21 is expressed as an interferon-stimulated gene, meaning the body ramps up production during infection, making it available across many tissue types.
A new target for infection therapeutics
This work reframes intracellular defense as a primary mode of immunity, not merely a backup. James stated that "without TRIM21, a significant component of protective immunity in vivo against viruses is lost," suggesting the pathway carries clinical weight in animal models.
The versatility of TRIM21 is the hook. Because TRIM21 responds to antibodies on the surface of pathogens rather than requiring a unique protein sensor for each invader, it can degrade structurally diverse targets—viruses with capsids, bacteria with cell walls, and potentially other large protein aggregates. That flexibility may explain why TRIM21 evolved broad substrate specificity.
The authors propose that antibodies or small-molecule drugs could be engineered to mark pathogens in the blood, allowing TRIM21 to recognize and jumpstart ADX once they enter cells. However, no such therapeutic has been tested, and the jump from mouse infection models to human clinical efficacy is substantial.
The team also flagged that TRIM21 may not be the only ADX-triggering protein. Other intracellular sensors could exist with equally broad or more specialized pathogen targets, opening additional therapeutic avenues.
What to do with this finding
Immunology researchers and infectious disease drug developers should examine whether existing antibody-based therapies could be optimized to enhance ADX. TRIM21 knockdown or overexpression studies in relevant cell types and in vivo infection models would test whether blocking or boosting the pathway affects clearance.
The microscopy platform Albecka developed for tracking TRIM21 and autophagosome assembly is a resource for the field. Researchers working on autophagy or intracellular pathogen defense can use similar high-fidelity confocal and super-resolution approaches to ask whether other E3 ubiquitin ligases or pattern-recognition receptors trigger selective autophagy of diverse substrates.
Caution: the therapeutic window is uncertain. TRIM21 upregulation could boost antiviral immunity but might also trigger excessive autophagy or off-target degradation of host proteins. The next phase will require careful dose-response work and safety profiling in animal models before any clinical candidate emerges.